Welcome to our dedicated page for Phibro Animal Health Corporation news (Ticker: PAHC), a resource for investors and traders seeking the latest updates and insights on Phibro Animal Health Corporation stock.
Phibro Animal Health Corporation (Class A, symbol: PAHC) is a leading global company specializing in animal health and mineral nutrition. With over 40 years of experience, Phibro is dedicated to meeting the rising demand for animal protein by focusing solely on animals used in food production. The company offers a comprehensive range of products for poultry, swine, beef and dairy cattle, and aquaculture.
Phibro's core business involves the development, manufacturing, and marketing of products designed to prevent, control, and treat animal diseases, enhance nutrition, and contribute to balanced mineral nutrition. Their product portfolio includes antibacterials, anticoccidials, nutritional specialty products, and vaccines. The company's operations are divided into three segments: Animal Health, Mineral Nutrition, and Performance Products, with the Animal Health segment being the primary revenue driver.
In the fiscal year ending June 30, 2017, Phibro reported net sales of $764 million. The company employs over 1,400 professionals who are committed to delivering value-based solutions to livestock producers, helping them maintain and enhance the health of their animals. Phibro's products are sold both in the United States and internationally, demonstrating its significant global footprint.
Recent achievements and ongoing projects by Phibro include the development of new vaccines and nutritional specialties aimed at improving animal health and productivity. The company continues to partner with various stakeholders in the livestock industry to innovate and provide sustainable solutions.
Phibro's financial condition remains robust, supported by consistent revenue streams from its diversified product offerings. The company’s focus on research and development underscores its commitment to advancing animal health technologies and addressing the evolving needs of the livestock industry.
For the latest news and updates, Phibro Animal Health Corporation remains a key player in the animal health sector, reflecting its dedication to enhancing the well-being of food animals globally.
Phibro Animal Health (PAHC) reported strong Q1 FY2025 financial results with significant growth across key metrics. Net sales increased 13% to $260.4 million, while net income rose to $7.0 million. The company achieved a 64% increase in Adjusted EBITDA to $30.7 million. Animal Health segment showed impressive performance with 14% sales growth. The company updated its FY2025 guidance, projecting net sales of $1.05-1.10 billion and Adjusted EBITDA of $124-132 million. Additionally, Phibro announced the discontinuation of its atopic dermatitis project while maintaining focus on companion animal investments.
Phibro Animal Health (Nasdaq: PAHC) announced that its Board of Directors has declared a quarterly cash dividend of $0.12 per share for both Class A and Class B common stock. The dividend will be paid on December 18, 2024, to stockholders recorded as of the close of business on November 27, 2024.
Phibro Animal Health (PAHC) has completed the acquisition of Zoetis' medicated feed additive portfolio and certain water-soluble products. The acquisition includes 37+ product lines across approximately 80 countries, six manufacturing sites in the U.S., Italy and China, and a team of over 300 employees. The portfolio is expected to enhance Phibro's profitability, EBITDA margin, and Adjusted Earnings Per Share. The deal expands Phibro's species and product portfolios across cattle, swine, and poultry sectors, complementing their existing lineup of vaccines, nutritional specialties, and mineral nutrition.
Phibro Animal Health (Nasdaq: PAHC) has scheduled its first quarter financial results announcement for Wednesday, November 6, 2024, after market close. The company will host a conference call and webcast to discuss the results on Thursday, November 7, 2024, at 9:00 AM Eastern Time. Investors can access the presentation through the company's investor website or by dialing in using the provided conference ID 3927884. A replay will be available approximately two hours after the event.
Phibro Animal Health (Nasdaq: PAHC) has announced its participation in the Morgan Stanley Annual Global Healthcare Conference. The company's Chief Financial Officer, Glenn David, and Chief Operating Officer, Larry Miller, will address financial analysts and investors on Thursday, September 5, 2024, at 1:05 PM ET at the New York Marriott Marquis.
The presentation will be available live via audio on the company's Investor Relations Website. For those unable to attend, a replay of the session will be archived and accessible on the same website. This event provides an opportunity for Phibro to engage with the financial community and share insights into its operations and strategy.
Phibro Animal Health (Nasdaq: PAHC) reported fourth-quarter and fiscal year 2024 results, showing mixed performance. Q4 Highlights: Net sales rose 7% to $273.2M; net income dropped $10.7M to $0.8M; diluted EPS fell by $0.26 to $0.02. Adjusted EBITDA increased 3% to $33.4M; adjusted net income rose 10% to $16.7M. Fiscal Year 2024 Highlights: Net sales grew 4% to $1.02B; net income decreased by $30.2M to $2.4M; diluted EPS dropped $0.75 to $0.06. Adjusted EBITDA fell 1% to $111.2M; adjusted net income dipped by 1% to $48.4M. Guidance for FY 2025: Net sales projected at $1.040B to $1.090B; adjusted EBITDA between $118M-$126M. CEO Jack Bendheim highlighted strength in Q4 performance and expects continued growth, especially in Animal Health.
Phibro Animal Health (Nasdaq: PAHC) has announced it will release its fourth quarter and fiscal year 2024 financial results on Wednesday, August 28, 2024, after market close. The company will host a conference call and webcast on Thursday, August 29, 2024, at 9:00 AM Eastern Time to discuss the results. Interested parties can access the webcast and presentation slides at https://investors.pahc.com. The call will also be available via phone, with separate numbers for U.S./Canada and international callers. A replay of the webcast will be available approximately two hours after the event concludes.
Phibro Animal Health (Nasdaq: PAHC) has announced a quarterly cash dividend of $0.12 per share on both its Class A and Class B common stock. The dividend is set to be paid on September 25, 2024, to stockholders of record as of the close of business on September 4, 2024. This decision was made by the company's Board of Directors, demonstrating their commitment to returning value to shareholders. The consistent dividend payout suggests financial stability and confidence in the company's future performance.
Phibro Animal Health (Nasdaq: PAHC) has released its third annual Environmental, Social, and Governance (ESG) Report, highlighting 2023 achievements. The report emphasizes Phibro's commitment to enhancing animal health and nutrition to promote sustainability. Significant efforts include disease prevention, waste reduction, and resource conservation, which contribute to a safer, more affordable food supply. These initiatives align with the UN's 2030 Sustainable Development Goals (SDGs). The report underscores the importance of the One Health approach, emphasizing interconnections among the health of people, animals, and the planet. Phibro’s work in 2023 focused on reducing greenhouse gas emissions, enhancing food production efficiency, and supporting farmers' economic stability. This contributes to mitigating climate change and promoting food security. The company aims to continue driving sustainability and ethical growth, ensuring positive global contributions.
Phibro Animal Health (Nasdaq: PAHC) announced its participation in the Stifel Annual Dental and Animal Health (Jaws & Paws) Conference.
Key executives including CFO Glenn David, COO Larry Miller, and EVP Corporate Strategy Daniel Bendheim will present to financial analysts and investors on May 29, 2024, at 10:20 AM ET, at the St. Regis New York.
The live audio presentation will be accessible on the Phibro Animal Health Investor Relations Website, with a replay available for later viewing.
FAQ
What is the current stock price of Phibro Animal Health Corporation (PAHC)?
What is the market cap of Phibro Animal Health Corporation (PAHC)?
What does Phibro Animal Health Corporation do?
Which animals does Phibro's products cater to?
What are the main product categories of Phibro Animal Health Corporation?
How many employees does Phibro Animal Health Corporation have?
How much revenue did Phibro report for the fiscal year ending June 30, 2017?
What are the primary segments of Phibro's operations?
Where does Phibro sell its products?
What recent projects is Phibro involved in?
Who are Phibro's primary customers?
What drives Phibro's revenue?
